Why Sorrento Therapeutics Stock Flew Nearly 7% Higher on Monday

·1-min read
Why Sorrento Therapeutics Stock Flew Nearly 7% Higher on Monday

The company got the green light to launch phase 2 testing in the U.K. for its experimental COVID-19 treatment.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting